Have a feature idea you'd love to see implemented?
Let us know!
EXEL Exelixis Inc
Price (delayed)
$26.31
Market cap
$7.5B
P/E Ratio
22.49
Dividend/share
N/A
EPS
$1.17
Enterprise value
$7.5B
Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work
Highlights
The company's EPS has surged by 129% YoY and by 83% QoQ
The company's net income has surged by 113% YoY and by 71% QoQ
EXEL's quick ratio is up by 25% since the previous quarter but it is down by 8% year-on-year
The company's equity fell by 16% YoY
Key stats
What are the main financial stats of EXEL
Market
Valuations
Earnings
Shares outstanding
285.25M
Market cap
$7.5B
Enterprise value
$7.5B
Price to earnings (P/E)
22.49
Price to book (P/B)
3.62
Price to sales (P/S)
3.78
EV/EBIT
16.64
EV/EBITDA
14.82
EV/Sales
3.73
Revenue
$2.01B
EBIT
$450.97M
EBITDA
$506.44M
Free cash flow
$277.54M
Per share
Balance sheet
Liquidity
EPS
$1.17
Free cash flow per share
$0.96
Book value per share
$7.28
Revenue per share
$6.96
TBVPS
$9.37
Total assets
$2.77B
Total liabilities
$653.39M
Debt
$198.02M
Equity
$2.12B
Working capital
$1.13B
Debt to equity
0.09
Current ratio
4.27
Quick ratio
4.05
Net debt/EBITDA
0
Margins
Efficiency
Dividend
EBITDA margin
25.1%
Gross margin
96.1%
Net margin
17.4%
Operating margin
18.3%
Return on assets
12.2%
Return on equity
15.8%
Return on invested capital
19.2%
Return on capital employed
18.6%
Return on sales
22.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EXEL stock price
How has the Exelixis stock price performed over time
Intraday
2.33%
1 week
-1.31%
1 month
-1.2%
1 year
22.37%
YTD
9.67%
QTD
1.39%
Financial performance
How have Exelixis's revenue and profit performed over time
Revenue
$2.01B
Gross profit
$1.93B
Operating income
$369.54M
Net income
$349.99M
Gross margin
96.1%
Net margin
17.4%
Exelixis's operating income has surged by 162% YoY and by 115% QoQ
EXEL's operating margin has surged by 123% year-on-year and by 97% since the previous quarter
The company's net income has surged by 113% YoY and by 71% QoQ
The net margin has soared by 81% YoY and by 57% from the previous quarter
Growth
What is Exelixis's growth rate over time
Valuation
What is Exelixis stock price valuation
P/E
22.49
P/B
3.62
P/S
3.78
EV/EBIT
16.64
EV/EBITDA
14.82
EV/Sales
3.73
The company's EPS has surged by 129% YoY and by 83% QoQ
The P/E is 49% below the last 4 quarters average of 42.8 and 43% below the 5-year quarterly average of 38.6
EXEL's P/B is 18% above its 5-year quarterly average of 3.0 and 10% above its last 4 quarters average of 3.2
The company's equity fell by 16% YoY
EXEL's price to sales (P/S) is 23% lower than its 5-year quarterly average of 4.8 and 2.9% lower than its last 4 quarters average of 3.8
The revenue has grown by 17% YoY and by 9% from the previous quarter
Efficiency
How efficient is Exelixis business performance
The company's return on equity has surged by 143% YoY and by 78% QoQ
The ROA has soared by 130% YoY and by 77% from the previous quarter
The ROIC has soared by 113% YoY and by 76% from the previous quarter
The company's return on sales has surged by 84% YoY and by 60% QoQ
Dividends
What is EXEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EXEL.
Financial health
How did Exelixis financials performed over time
EXEL's quick ratio is up by 25% since the previous quarter but it is down by 8% year-on-year
EXEL's current ratio is up by 23% since the previous quarter but it is down by 9% year-on-year
The debt is 91% less than the equity
The company's equity fell by 16% YoY
The company's debt to equity rose by 13% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.